It is an anti-inflammatory and anti-fibrotic agent that down-regulates transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF-α), inhibits collagen synthesis and reduces fibroblast proliferation; the agent is licensed for the treatment of patients with mild-to moderate IPF in European Union and IPF in the United States [1,11]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.